The presence of mutated TP53 is reported to be an adverse predictor of TKI therapeutic outcome in NSCLC.26 We next examined the temporal changes in the mutational profiles of TP53, an established tumor initiator gene. This evidence concerns the gene TP53 and non-small cell lung carcinoma.